Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab

Katsunori Masaki, Shigeharu Ueki, Keiji Tanese, Genta Nagao, Sho Kanzaki, Eri Matsuki, Hidehiro Irie, Hiroki Kabata, Jun Miyata, Ichiro Kawada, Koichi Fukunaga

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


A 56-year-old woman presented with repeated swelling of the lips and face. She had a history of childhood asthma; she had a recurrence of asthma when she was 54 years old and was taking inhaled corticosteroids, and other antiasthma drugs. The swelling of her lips and face improved temporarily with oral corticosteroids (OCS), but recurred soon after discontinuing OCS. Her peripheral blood eosinophil count was 632/μL (9.3%), and her serum was negative for myeloperoxidase-anti-neutrophil cytoplasmic antibody and serine proteinase3-anti-neutrophil cytoplasmic antibody. Hematoxylin and eosin staining of her back skin revealed abundant eosinophilic infiltrate around the vascular area of the shallow dermis layer, but no evidence of vasculitis and we diagnosed her as eosinophilic annular erythema (EAE). Punctate staining of galectin-10, chromatolytic eosinophils, and net-like DNA was also evident in close proximity to the free granules, indicating extracellular vesicles and eosinophil extracellular traps (ETosis). We started daily OCS to control her asthma and skin eruption/oedema. Three months after administering daily OCS, benralizumab was initiated for withdrawal from OCS dependence and treatment of severe asthma. After initiation of benralizumab, her skin and subcutaneous tissue symptoms promptly improved. OCS was discontinued, and no edematous erythema has been observed since then. Bronchial asthma has also been well-controlled. This is the first report on the evidence of eosinophil ETosis in the dermis of EAE patients and the efficacy of benralizumab in a patient with EAE. Benralizumab may be a useful drug for treating refractory EAE with severe eosinophilic asthma.

Original languageEnglish
Article numbere28
JournalAsia Pacific Allergy
Publication statusPublished - 2021 Jul


  • Angioedema
  • Asthma
  • Benralizumab
  • ETosis
  • Eosinophil

ASJC Scopus subject areas

  • Immunology and Allergy
  • Dermatology


Dive into the research topics of 'Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab'. Together they form a unique fingerprint.

Cite this